entertainment -WSS

entertainment

author：explore 2025-10-01 10:36:06 - browse：98

FDA-Blood Sugar Monitor — The FDA has approved a device from Abbott that continuously monitors diabetics’ blood sugar levels without requiring backup finger prick tests. Abbott Laboratories via AP

U.S. regulators have approved the first continuous blood sugar monitor for diabetics that doesn’t need backup finger prick tests.

Current models require users to test a drop of blood twice daily to calibrate, or adjust, the monitor.

The pain of finger sticks and the cost of testing supplies discourage many people from keeping close tabs on their blood sugar, which is needed to manage insulin use and adjust what they eat.

Abbott’s new FreeStyle Libre Flash Glucose Monitoring System, approved Wednesday by the Food and Drug Administration, uses a small sensor attached to the upper arm. Patients wave a reader device over it to see the current blood sugar level and changes over the past eight hours.

Most of the 30 million Americans with diabetes use standard glucose meters, which require multiple finger pricks each day and only show current sugar level. More-accurate continuous glucose monitoring devices are used by about 345,000 Americans.

Newsletters

Sign up for Morning Rounds

Your daily dose of news in health and medicine.

Please enter a valid email address. Privacy Policy

But most don’t do the finger pricks to calibrate them and may get inaccurate readings, said Dr. Timothy Bailey, who helped test FreeStyle Libre.

“We’re able to lower blood sugar safely” with this technology, said Bailey, director of the Advanced Metabolic Care and Research Institute in California. He receives consulting fees from various diabetes device makers.

Too-high blood sugar levels can damage organs and lead to heart attacks, strokes, blindness and amputations. Very low blood sugar can cause seizures, confusion and loss of consciousness.

Abbott’s device was approved for adults with type 1 or type 2 diabetes and should be available in pharmacies within months. The company, based near Chicago, did not disclose the price of the reader or the sensors.

Abbott’s system can’t be used with an insulin pump, a device worn against the skin that allows users to inject insulin as needed, but the company is planning improvements to eventually enable that.

Rival Medtronic this spring launched a device in which the insulin pump automatically responds to blood sugar changes recorded by the sensor and either withholds or injects insulin as needed.

— Linda A. Johnson

Previous article： Activists slam private health insurers over coverage restrictions
Next article： Padmanee Sharma of MD Anderson at center of lawsuit over credit

leisure time

WSS

Texas Medical Board asked to define abortion emergency exception

Problems with a popular proposal to regulate AI in health care

Novo Holdings to buy drug manufacturer Catalent in $16.5B deal

A protest over insulin prices is seen as a fight for life

Texas Medical Board asked to define abortion emergency exception

Eight reasons why you should get an updated Covid vaccine

hotspot

entertainment

Sign up for Morning Rounds

knowledge

After affirmative action ruling, medical educators look to 'holistic review'

Takeaways from AdvaMed, the largest medical devices conference

Medical leaders decry Supreme Court decision on affirmative action

Texas Medical Board asked to define abortion emergency exception

Peter Hotez and the public health issue of online harassment

Cano Health’s bankruptcy is a warning for Medicare Advantage

Trump demands the U.S. pay no more for drugs than other countries … again

Readout LOUD podcast: Merger Mondays, Ozempic panic

Walensky prepares to leave CDC — and Congress — behind

What's changing in Medicare's open enrollment this year?

Wikipedia

A fraught question for the kids of Alzheimer’s: Is it coming for us?

European regulators consider appeal over Amylyx ALS drug

Top private equity targets in 2023: cardiology, clinical trials, lasers

A fraught question for the kids of Alzheimer’s: Is it coming for us?

AstraZeneca stays mum on Medicare drug pricing negotiations

A revolution in caring for preterm infants

focus

leisure time

hotspot

knowledge